• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti-viral therapy.

作者信息

Yip Terry Cheuk-Fung, Wong Vincent Wai-Sun

机构信息

Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.

Medical Data Analytics Centre (MDAC), The Chinese University of Hong Kong, Hong Kong SAR, China.

出版信息

Aliment Pharmacol Ther. 2021 Sep;54(5):722-723. doi: 10.1111/apt.16498.

DOI:10.1111/apt.16498
PMID:34379832
Abstract
摘要

相似文献

1
Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti-viral therapy.社论：对于接受抗病毒治疗的亚洲慢性乙型肝炎患者，中心性肥胖是肝细胞癌的一个危险因素。
Aliment Pharmacol Ther. 2021 Sep;54(5):722-723. doi: 10.1111/apt.16498.
2
Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti-viral therapy-authors' reply.社论：中心性肥胖是接受抗病毒治疗的亚洲慢性乙型肝炎患者肝细胞癌的危险因素——作者回复
Aliment Pharmacol Ther. 2021 Sep;54(5):724-725. doi: 10.1111/apt.16548.
3
Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy.中心型肥胖与接受抗病毒治疗的慢性乙型肝炎患者肝细胞癌的相关性。
Aliment Pharmacol Ther. 2021 Aug;54(3):329-338. doi: 10.1111/apt.16469. Epub 2021 Jun 22.
4
Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors' reply.社论：接受替诺福韦或恩替卡韦治疗的慢性乙型肝炎患者发生肝细胞癌的风险相似——来自欧洲的新线索。作者回复
Aliment Pharmacol Ther. 2021 Mar;53(5):659. doi: 10.1111/apt.16251.
5
Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.慢性乙型肝炎患者中，替诺福韦与恩替卡韦相比引发肝细胞癌的风险
Gastroenterology. 2020 Jun;158(8):2310-2311. doi: 10.1053/j.gastro.2019.11.314. Epub 2020 Mar 19.
6
Is Tenofovir Associated with a Lower Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Compared With Entecavir?与恩替卡韦相比，替诺福韦在慢性乙型肝炎患者中是否与较低的肝细胞癌风险相关？
Gastroenterology. 2020 Jun;158(8):2311-2312. doi: 10.1053/j.gastro.2020.02.062. Epub 2020 Mar 19.
7
Editorial: incorporating liver stiffness to risk scores for HCC in patients with chronic hepatitis B treated with oral antivirals: ready to use or not?
Aliment Pharmacol Ther. 2021 Mar;53(6):753-754. doi: 10.1111/apt.16279.
8
Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors.抗病毒治疗时代乙型肝炎病毒相关肝细胞癌：非病毒危险因素的新作用。
Liver Int. 2020 Oct;40(10):2316-2325. doi: 10.1111/liv.14607. Epub 2020 Aug 3.
9
Editorial: similar risk of hepatocellar carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe.社论：接受替诺福韦或恩替卡韦治疗的慢性乙型肝炎患者患肝细胞癌的风险相似——来自欧洲的新线索
Aliment Pharmacol Ther. 2021 Mar;53(5):657-658. doi: 10.1111/apt.16238.
10
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.在患有慢性乙型肝炎的白种人患者中，长期使用恩替卡韦或替诺福韦治疗期间肝细胞癌风险相似。
J Hepatol. 2021 Jan;74(1):245-246. doi: 10.1016/j.jhep.2020.07.038. Epub 2020 Sep 30.

引用本文的文献

1
Effects of Hayata juice on high-fat diet-induced obesity in HBV transgenic mice.早田汁对乙肝病毒转基因小鼠高脂饮食诱导肥胖的影响。
Heliyon. 2024 Jan 10;10(2):e24438. doi: 10.1016/j.heliyon.2024.e24438. eCollection 2024 Jan 30.